Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5705540 | Ophthalmology | 2016 | 8 Pages |
Abstract
Treatment of noninfectious uveitis with adalimumab is associated with high rates of favorable clinical response. Overall, adalimumab trough levels were higher in responder patients. Development of permanent AAA was associated with undetectable trough adalimumab levels and worse uveitis outcome. Immunogenicity was more common in patients in whom uveitis was associated with a systemic disease and was not influenced by concomitant immunosuppressors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Miguel MD, PhD, Sara MD, Irene MD, Ana M. MD, Carolina MD, Manuel MD, Jose G. MD, PhD,